Suppr超能文献

白藜芦醇和姜黄素用于治疗恰加斯病——一项系统评价

Resveratrol and Curcumin for Chagas Disease Treatment-A Systematic Review.

作者信息

Imperador Carlos Henrique Lima, Scarim Cauê Benito, Bosquesi Priscila Longhin, Lopes Juliana Romano, Cardinalli Neto Augusto, Giarolla Jeanine, Ferreira Elizabeth Igne, Dos Santos Jean Leandro, Chin Chung Man

机构信息

Advanced Research Center in Medicine (CEPAM), School of Medicine, Union of the Colleges of the Great Lakes (UNILAGO), Sao Jose do Rio Preto 15030-070, SP, Brazil.

Laboratory of Drug Design (LAPDESF), School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Araraquara 14800-903, SP, Brazil.

出版信息

Pharmaceuticals (Basel). 2022 May 15;15(5):609. doi: 10.3390/ph15050609.

Abstract

Chagas disease (CD) is a neglected protozoan infection caused by , which affects about 7 million people worldwide. There are two available drugs in therapeutics, however, they lack effectiveness for the chronic stage-characterized mainly by cardiac (i.e., cardiomyopathy) and digestive manifestations (i.e., megaesophagus, megacolon). Due to the involvement of the immuno-inflammatory pathways in the disease's progress, compounds exhibiting antioxidant and anti-inflammatory activity seem to be effective for controlling some clinical manifestations, mainly in the chronic phase. Resveratrol (RVT) and curcumin (CUR) are natural compounds with potent antioxidant and anti-inflammatory properties and their cardioprotective effect have been proposed to have benefits to treat CD. Such effects could decrease or block the progression of the disease's severity. The purpose of this systematic review is to analyze the effectiveness of RVT and CUR in animal and clinical research for the treatment of CD. The study was performed according to PRISMA guidelines and it was registered on PROSPERO (CDR42021293495). The results did not find any clinical study, and the animal research was analyzed according to the SYRCLES risk of bias tools and ARRIVE 2.0 guidelines. We found 9 eligible reports in this study. We also discuss the potential RVT and CUR derivatives for the treatment of CD as well.

摘要

恰加斯病(CD)是一种由[病原体名称缺失]引起的被忽视的原生动物感染,全球约有700万人受其影响。治疗方面有两种可用药物,但它们对以心脏(即心肌病)和消化系统表现(即巨食管、巨结肠)为主的慢性阶段缺乏疗效。由于免疫炎症途径参与了该疾病的进展,具有抗氧化和抗炎活性的化合物似乎对控制某些临床表现有效,主要是在慢性期。白藜芦醇(RVT)和姜黄素(CUR)是具有强大抗氧化和抗炎特性的天然化合物,其心脏保护作用已被认为对治疗恰加斯病有益。这些作用可能会降低或阻止疾病严重程度的进展。本系统评价的目的是分析白藜芦醇和姜黄素在动物和临床研究中治疗恰加斯病的有效性。该研究按照PRISMA指南进行,并在PROSPERO(CDR42021293495)上注册。结果未发现任何临床研究,动物研究根据SYRCLES偏倚风险工具和ARRIVE 2.0指南进行分析。我们在本研究中发现了9篇符合条件的报告。我们还讨论了用于治疗恰加斯病的潜在白藜芦醇和姜黄素衍生物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24da/9143057/377760236400/pharmaceuticals-15-00609-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验